Seres Therapeutics, Inc. (MCRB)
| Previous close | 3.3400 |
| Open | 3.3400 |
| Bid | 3.3500 x 1800 |
| Ask | 3.3600 x 900 |
| Day's range | 3.2613 - 3.4550 |
| 52-week range | 3.2200 - 25.0550 |
| Volume | |
| Avg. volume | 758,065 |
| Market cap | 317.273M |
| Beta (5Y monthly) | 3.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9440 |
| Earnings date | 01 Aug 2022 - 05 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.50 |
- Business Wire
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
CAMBRIDGE, Mass., May 10, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which is taking place May 21-24, 2022. SER-109 is an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). With an oral and poster presentation, Seres will present data on how SER-109 restores the f
- Simply Wall St.
Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Slashed This Year's Revenue Estimates By 59%
Market forces rained on the parade of Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders today, when the analysts...
- Zacks
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
